TRPC7-AS1: A Potential Drug Target and Biomarker (G100874024)

Target Name: TRPC7-AS1

NCBI ID: G100874024

TRPC7-AS1

Other Name(s): TRPC7 antisense RNA 1

TRPC7-AS1: A Potential Drug Target and Biomarker

TRPC7 (Transient receptor potential cation channel subfamily 7) is a family of G protein-coupled receptors that play a crucial role in cellular signaling. The TRPC7 gene has been identified as a potential drug target and a biomarker for various diseases, including cancer, neurodegenerative disorders, and psychiatric disorders. In this article, we will discuss TRPC7-AS1, a TRPC7 receptor that has been targeted by drug developers and researchers as a potential drug target and biomarker.

TRPC7-AS1: Structure and Function

TRPC7-AS1 is a 7-transmembrane protein that consists of an extracellular domain, a transmembrane domain, an intracellular domain, and a unique N-terminal region called the AS1 region. The TRPC7-AS1 receptor has a pore-like structure that allows it to interact with various signaling molecules, including small molecules, ions, and neurotransmitters.

The TRPC7-AS1 receptor is composed of four subunits, each composed of a catalytic 伪尾 subunit and a non-catalytic 纬未 subunit. The 伪尾 subunit consists of a nucleotide-binding oligomerization domain (NBD), a zinc ion-binding domain (ZBD), and a carboxylic acid-binding domain (CBD). The NBD and ZBD domains play crucial roles in the receptor's signaling pathway.

TRPC7-AS1 Receptor Signaling

TRPC7-AS1 is a potent modulator of various physiological processes, including pain perception, neurotransmission, and cell signaling. The TRPC7-AS1 receptor has been shown to play a crucial role in pain perception and neurotransmission.

TRPC7-AS1 has been shown to interact with various neurotransmitters, including opioids, GABA, and glutamate. Studies have shown that activation of the TRPC7-AS1 receptor can lead to the release of these neurotransmitters, which can then modulate various cellular processes, including pain perception, neurotransmission, and gene expression.

TRPC7-AS1 has also been shown to play a role in cell signaling. The TRPC7-AS1 receptor has been shown to interact with various signaling molecules, including T-cell signaling, stem cell proliferation, and neuroprotection.

TRPC7-AS1 as a Potential Drug Target

TRPC7-AS1 has been identified as a potential drug target due to its involvement in various diseases, including cancer, neurodegenerative disorders, and psychiatric disorders.

TRPC7-AS1 has been shown to be overexpressed or underexpressed in various diseases, including cancer, neurodegenerative disorders, and psychiatric disorders. Overexpression of the TRPC7-AS1 receptor has been shown to contribute to the development and progression of these diseases.

TRPC7-AS1 has also been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and psychiatric disorders. The levels of TRPC7-AS1 have been shown to be altered in the brains of individuals with various psychiatric disorders, including depression, anxiety, and schizophrenia.

TRPC7-AS1 as a Potential Biomarker

TRPC7-AS1 has been shown to be a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and psychiatric disorders. The levels of TRPC7-AS1 have been shown to be altered in the brains of individuals with

Protein Name: TRPC7 Antisense RNA 1

The "TRPC7-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRPC7-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets